Tecartus FDA Approved for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Web Exclusives - FDA Approvals

On October 1, 2021, the FDA accelerated the approval of a new indication for brexucabtagene autoleucel (Tecartus; Kite Pharma), a CD19-directed CAR T-cell therapy, for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The FDA granted brexucabtagene autoleucel breakthrough therapy and orphan drug designations for this indication.

This approval was based on the ZUMA-3 study, a single-arm multicenter clinical trial of adults with relapsed or refractory B-cell precursor ALL. Patients received a single infusion of brexucabtagene autoleucel after completion of lymphodepleting chemotherapy.

The efficacy measures were complete response (CR) within 3 months after receiving the CAR T-cell infusion, and the duration of the CR. Of the 54 patients evaluable for efficacy, 28 (52%; 95% confidence interval, 38-66) achieved CR within 3 months. At a median follow-up of 7.1 months, the median duration of CR was not reached, and the duration of CR was estimated to be >12 months for >50% of the patients.

The most common (≥20%) nonlaboratory side effects included fever, cytokine-release syndrome, hypotension, encephalopathy, tachycardias, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting.

Related Items
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
Web Exclusives published on May 19, 2022 in FDA Approvals
Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker
Web Exclusives published on May 16, 2022 in FDA Approvals
Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma
Web Exclusives published on May 5, 2022 in FDA Approvals
Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma
Web Exclusives published on May 3, 2022 in FDA Approvals
Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer
Web Exclusives published on April 26, 2022 in FDA Approvals
Last modified: February 16, 2022
Copyright © Engage Healthcare Communications, LLC. All rights reserved.